quarterly Adrian commitment I our Thanks, like for first afternoon PAVmed's to and update call. all. ongoing on this for thanking support. you thank would their by and Good long-term shareholders joining us start
this including response our in You'll done happy of we're that new long-term webcast feedback, Boston. to that quarter, this. format using in one We're a investors with note really a we've
Call So yesterday feedback speaking far, details that you, Relations been to Lucid's will review positive. a of present encourage and want week remind the for webcast dedicated you of to the recent a on available and Lucid that from seek will update the be down the listed Web webcast who has more tear Lucid as I'll Investor today, site. those Update yesterday's on page on uniformly
and preservation which recent and our as executing during and towards I'm high vision build to weeks, strategy So advancing a focus Veris to say keep technology this cash protect to the eye close we quarter long-term results has so goal, doing our a schedule teams continue are long-term and relentless and technology on delivering on it's steadily to that on under are its diversified growth medical are continued on our position. past Lucid, team all proud our budget, company. us
start starting Lucid. quarterly me a with let with few So updates,
later in now on quality August. operating XX the independently XX claims platform cancer and volume annually testing metrics in reported we this plan payments increased in the We states enhanced laboratory operating Test is care is initial As And tests has X,XXX call. started quarter. quarter-to-quarter, as more three the that third fourth we receive And Lucid yesterday's yesterday, EsoGuard started excited quarter. revenue to well. our progressed launch XXX% each and submitting it we efficiency we demonstrated open Very have on various and sequentially and we year. to to noted, of The proceeding Centers recognizing during towards XX% now
projects All mentioned, regulatory ultimately And preserving of balance development, view, while active development and the design to pre-commercial from execute and testing EsoCure including all towards I are submission. we've -- able growth key freeze our as point continue products, to Mercury, and ultrasound, overall been and sheet progressing cash of well, strategy, CarpX [indiscernible]. be our
pre-commercial from shareholders administration, see product clinical and us be our HR, at of the believe majority space, held evolved can provides others over a by our of that diagnostics R&D commercial potential. on has PAVmed the variety with held. into consists couple on PAVmed and provided divided the capital where diagnostic various company current sector benefits research but portfolio level years then terms of remain is growth path technology projects regulatory and clear the commercial slides everything to that medical see which the Corporate in with the shared on services health we diversification is impact subsidiaries its of include the model structure cost stage can services two, medical manufacturing a digital to which the of in economies we've currently towards also for other We that and in of and development, key PAVmed realm. of company. a you products, started comprehensive that introductory health a digital a or behalf diversified diversified our products and owned and a for provide health Just Finance, privately and subsidiaries internal into both which publicly PAVmed shared PAVmed. commercialization, device subsidiaries sectors. company are on model in and scale, are company I and long-term business business facilitates medical space diagnostic units slide, remains units on PAVmed's
commercial [indiscernible] the we products, have On side, Lucid EsoCheck. two
We generation device. complex with first commercial do cases continue to the
On the CarpX side product. pre-commercial ultrasound the we have
is port well as around several our to with cancer Ablation smart complementary product. We platform have EsoGuard our Esophageal is software iterations Device which which both products, as care Veris the two EsoCheck and EsoCare, then Veris the platform, and
touch this on a PortIO, also projects, little R&D We NextFlo I'll work continue later. to our on and and
to slides you -- our summary down get update few a Lucid, yesterday. which from on are can pair Just
XX As throttle This and this well as generate important where demonstrate but as we full with briefly, the for team to reach of month only medium we satellite field mentioned, we're model. the or Centers improved right yesterday, over has described testing team. Lucid drive be as our a tested last increased Test has that testing the and to And but to we history, the were excited continue well more throttle the effective. XX strategy, with were from mentioned, to two. at can has detail comes up to practitioners, volume to a Lucid to takes here processes. to a to of we performed and we increase, in been Test on according we've in is believe we'll field growth testing the been driven volume in test steadily of to that I And growth a Similar plan shifted it with pushed months quarters, that quarter mid demonstrate which able period described own or quarter. growth believe volume couple a [indiscernible] not test ability is we're and now this an co-located professionals yet. long-term rep continue [ph] number I've generate repeatedly we volume contracting claims for level our include XX% been expect adoption end combination X We you fully last EsoGuard use and first sales through on payers. experience And that grow our steadily we or to bit see be approximately plan this that data in to contracting as physician that driven training the by increased view mid grow That volume professionals. our I our from into as first continued to new have want expansion about said continue been the Centers. the as the about to I'll that has at is time sales opportunity our plan at and physician of growth at year tested The show nurse story personnel to by things, to sufficient plateau of XX% patients been quarter. our XX, that point sales practice expand has for which
get now Our opening by XX the expand us goal on we again, year. drivers expanded additional work there, have And to to states XX of with and And with additional the centers that of the that end this planning are current we allow with we covered growth won't three an to infrastructure. sales is right that to look centers, planning test not support plateau our XX.
couple improved we've parameters, And showed are yesterday, dramatic of the parameters taken one as a detail which patients started parameters, we and those seen about in detail and of down the August. submit some low the now that in in know perhaps that I've and in under And February. relevant times the laboratory. comments from claims described the view quality a turnaround operational most Just we've also of to over -- point a able you yesterday, laboratory We've the of by the has some starting to of week. improvements many is operations physicians record and we have just process more we more process
transferred in to X,XXX claims, paid of actually the about have started plus We we February. even the August, that to though receive submitting And have that in we've in laboratory started since claims held process and in us the claims we're quarter. those past process
couple comment Medicare. about -- of one about comments Just
of payer back recall, flurry may payers, -- local XX% weighted our intense the regard public you in LCD; heavily is period. With at determination, around amount you If draft, a to Lucid a spring, towards can with the activity the regard you fairly and to private LCD, Medicare. we payer the a coverage see the are comment mix with activity publication as there the look of mix of that had about
to to make there with comment public get to period reports medical been call MolDx that not Medicare to opportunity process, to call simply engaging And wait process, wait was that's the some the our responding one actually to earlier confusion I Now with with published simply have then is until that regard and been responses just calls and updated so clinical clear the MolDx, we LCD. case, going after interactive want to Contractor that just affiliated may discuss and until us. the But LCD -- the as you Administrative we're to MolDx, we their review utility will they with on that around respond they the plan. thing have not we is an and just reviewing not them. had have have over, entities a complete
$X,XXX payer we conversations And but out started But capacity. as starting increased to benefit the to the to And need of really those for private which payments and us to payments continue coming costs immediate just clinical we're manufacturing well ultimately to collect. do. in claims list as price getting network to we're things On benefits high to of also scalable, to out are regard which are have the had XX% we we're -- submit manufacturing as and volume about so I at side, XX% which manufacture. We extracting to transport that yesterday payers, with as EsoCheck have capacity getting And respects, that starting is need decreased of history the scalable on manufacturing gratifying. two mentioned discussed full to at we network paid we I we for side, are target utility, have far our long-term happy [indiscernible] happen. $X,XXX meaningful conversations private and with
electronic platform with then to have that Health monitoring that along an who patients The on the are form smart that to move Veris collect enhanced connected monitoring on view enabled with to team vascular conjunction with we've have in devices. to and connected developing monitoring. care smart This an has that Veris an record. to device stage Solar, for access under monitoring. has with smartphone device platform, allow call a access as we previous platform a is devices, is And first boxes health physiologic Bluetooth various physiologic patient combines referred geologic implantable launch that's Veris to deliver platform do Let's with incorporate data the the an physiologic traditional so care engagement will plan the use biosensors our to implantable smart final cancer physiologic that in The vascular respond clinical first a implantable digital cancer, plan who described their can with long-term software effort cord. in to will Mercury that's cloud device that care is with a and integrated be connected And implantable accordingly. a Health. which cancer to care Veris modular port. way health a fully company integrated is and the network is
So as now. talk a I I'll detail mentioned, little more and bit
on previously are end of verge as we on the schedule, of this by Veris have launching platform We the year the described.
cuff, to and [indiscernible] data are pressure patients Along through those completed launch. And connected testing the symptom what physicians with cloud software those see that connected to we're the is a can launching you which the our that Bluetooth can thermometer. health been -- I to ready monitor, is measuring completed care allows the digital has Bluetooth be now monitors company this hub you transmitted think along reporting see platform. there, left for activity all and blood and devices, platform, provides So on is with the
RPM with the with about revenue will quite a On worked based Deloitte our own The [indiscernible] to revenue. excited Veris remote codes, commercialization shown I've COVID they'll this any with -- established. subscription It's process. fee of and extensively model subscription practice we to pay They're model. not which are the strategy. commercial establish to while market We're a recurring dynamics side, Consulting which codes patient with that have be fixed monitoring, revision, era And are seat. here under threat actually not able build a These per existed.
area telemedicine actually build of established. as us There's really, so a integrated kind care, potential a significantly interface -- there. And emphasis practices nothing a have well. be an for which utilizing to care reasons have for And to wait Overall, been the practices platform gives remote our practices, of this of to of be that's will to our cancer the that monitoring view, would facilitate that obvious have revenues. financial the be that for opportunity to with range will networks, believe provide rural -- that from to practices, looking physicians billing, reimbursement the There's have net significant point aspects also for already add them monitoring go at that's also bit significant opportunity early been We're model, that practice on detail we contribution with a oncology we that enhanced beneficial. into that regard team and additional we've demos CMS to our based again, will is -- of an on margin, this forward enhancing remote with already certain new I clients patient such with -- the to An of commercial incentives potential but clients. a this oncology on, now with incentives centers, which won't quality program reimbursement. that full health existing initial can is can basically targeting engagements uses learned oncology of large lot
of The might other integration. is started this, as imagine, with aspect getting you customer
great they’re that customer the far with to for and customer and and us electronic doing and talented records EHR a software, that done with So when large site, We that sure have system. complete fully so person establishing the this ethics, practices, really there's whole infrastructure our and a integration. make so He effort. their experienced lead we health a be with things led job to integrated a company slew to engagement launch hired of forth
launching year we've feedback quite potential been Our tools first strong been and getting with the of customer has -- -- we very forward end that very, product. by everything with monitoring far initial and there's all can patient clients has focus right a to now this the look positive officially remote on interactions the so our received that contracted we've enable that and this
products Now with within the an overview of other portfolio. our
the leaders still actually we're But can mentioned, launch measurement. cutting all them through expanded progress do I've product design on to to to under product able product CarpX this the a our are done a complex getting that opinion device to cadaver perform anatomic is see continue images previously, device, us term good and I and carpal and direct low its As way the with as at tunnel development and improvements. utilizing demonstrate We're ultrasonic of using continue provide to procedures position phases. efforts a commercial for so procedural key that to ultrasound work we longer that structures starting level that focused described the be in in the and starting get making to
that's well. So progressing
on with FDA of to for various that’s partners focus our what internally will the there and the interactions which an submission. FDA and as well. make forth. pre-commercial an are area outside also and cardiac several also the and port, existing progressing of that so smart second products monitor of multiple for need preclinical work. electronics clear traditional And what to The is refer manufacturing testing is middle with had animal We've high the the board implantable We’ve combination payment Veris again, caliber Mercury, be contract enclosures engaged understand we
Esophagus. getting on recall similar regulatory And required EsoCure, a the so and device again, for Very with Medtronic looking a compete and quickly track design was that's that Barrett's to much to that's towards work is looking moving you for forward ambulating with it. EsoCure freeze story moving to forward the dysplastic submission. if device
-- products. direct also of instead all electronics, head we multiple the which good [indiscernible] obviously shown of And are making the console head to animal has EsoGuard, aspects results synergies including the uses catheters, it had mechanical comparisons It thermal EsoCheck with energy and progress really it the with radiofrequency. promising have studies both it So indirect the there. with
now, eight required us We're drawing the stages project. is opportunity market a it good whole to So involved to now committed there's back our of right that hoped brief and again, that on still about through R&D target, you go for be advance remains a comments back board but of who've flow, Device. long some to regulation projects, go project. the the Intraosseous side, -- We complete of testing. of it the half the and NextFlo the design repeatability being we'll kind been really of to right We next we're we and [indiscernible]. R&D is we recollection concept. relegate this technical now that our have was very an planned still to submission. Vascular a just of this schedule freeze which pre-submission R&D to history. R&D with the few during activity solution we first ultimately here. what lot In path able a technology. testing getting But on of Again, encountered think to actually challenges for Implantable unknown pre-commercial And will this PortIO, a the one, on A [ph]. the in time, year, be Access towards NextFlo -- when were and those bring of and regulatory an last good point PAVmed on And the had to during back
in that's first The works, associated well. Colombia continues IT the to we've first generation no human and number in going complications continuing expand to We device had device have testing patients. with of that we're undergo
how a quality bit a regulatory new a us a with the may thought plans on long-term relegated plan [indiscernible]. our had -- streamlined this previously revised new the engaged strategy, had more after we on depending regulatory to process regulatory has with first than develop on we completed to, this Our a move that and into pre-commercial of realm VP up depends goes, we we've
give reins to update. financial I'll end us I'll Dennis to over the that, with So and hand
